Krug, U. ; Berdel, W. E. ; Gale, R. P. ; Haferlach, C. ; Schnittger, S. ; Müller-Tidow, C. ; Braess, J. ; Spiekermann, K. ; Staib, P. ; Beelen, D. ; Serve, H. 
; Schliemann, C. ; Stelljes, M. ; Balleisen, L. ; Maschmeyer, G. ; Grüneisen, A. ; Eimermacher, H. ; Giagounidis, A. ; Rasche, H. ; Hehlmann, R. ; Lengfelder, E. ; Thiel, E. ; Reichle, A. ; Aul, C. ; Ludwig, W.-D. ; Kern, W. ; Haferlach, T. ; Köpcke, W. ; Görlich, D. ; Sauerland, M. C. ; Heinecke, A. ; Wörmann, B. J. ; Hiddemann, W. ; Büchner, T.
; Schliemann, C. ; Stelljes, M. ; Balleisen, L. ; Maschmeyer, G. ; Grüneisen, A. ; Eimermacher, H. ; Giagounidis, A. ; Rasche, H. ; Hehlmann, R. ; Lengfelder, E. ; Thiel, E. ; Reichle, A. ; Aul, C. ; Ludwig, W.-D. ; Kern, W. ; Haferlach, T. ; Köpcke, W. ; Görlich, D. ; Sauerland, M. C. ; Heinecke, A. ; Wörmann, B. J. ; Hiddemann, W. ; Büchner, T. 
Abstract
We randomized 3375 adults with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome to test whether increasingly intensive chemotherapies assigned at study-entry and analyzed on an intent-to-treat basis improved outcomes. In total, 1529 subjects <60 years were randomized to receive: (1) a first course of induction therapy with high-dose cytarabine and mitoxantrone ...
Owner only: item control page
Altmetric